<DOC>
	<DOCNO>NCT01159769</DOCNO>
	<brief_summary>The purpose study evaluate patient perception olopatadine 0.2 % dosed daily patient previously treat twice-daily , topical , ocular , anti-allergy medication .</brief_summary>
	<brief_title>Patient Perceptions Quality Life Associated With Use Olapatadine 0.2 % Treatment Allergic Conjunctivitis</brief_title>
	<detailed_description />
	<mesh_term>Conjunctivitis</mesh_term>
	<mesh_term>Conjunctivitis , Allergic</mesh_term>
	<mesh_term>Olopatadine Hydrochloride</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<criteria>12 year age old . History ( within past 24 month ) allergic conjunctivitis . Active sign symptom ocular allergy . Ocular health within normal limit , determine investigator subinvestigator . Willing avoid contact lens wear study visit immediately prior study medication instillation 10 minute instillation study drug . Other protocoldefined inclusion criterion may apply . Contraindications hypersensitivity study medication component . One sight eye correctable 0.6 logMAR well eye screen visit . Known history recurrent corneal erosion syndrome . Ocular trauma surgical intervention within 6 month prior Visit 1 . Participation investigational study within 30 day Visit 1 . Pregnant nursing . Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Allergic conjunctivitis</keyword>
</DOC>